Vital Therapies, Inc. (NASDAQ:VTL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, May 10th.
According to Zacks, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. “
Separately, BTIG Research reiterated a “hold” rating on shares of Vital Therapies in a report on Friday, March 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Vital Therapies has an average rating of “Hold” and an average target price of $8.00.
Shares of Vital Therapies (VTL) traded down 3.23% during mid-day trading on Wednesday, reaching $3.00. The company had a trading volume of 78,199 shares. Vital Therapies has a one year low of $2.25 and a one year high of $8.15. The stock has a 50 day moving average of $3.24 and a 200-day moving average of $4.18. The firm’s market capitalization is $126.62 million.
Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.02. During the same quarter last year, the company earned ($0.31) EPS. Equities analysts predict that Vital Therapies will post ($1.67) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Vital Therapies, Inc. (VTL) Upgraded at Zacks Investment Research” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/06/15/vital-therapies-inc-vtl-raised-to-hold-at-zacks-investment-research-updated-updated-updated.html.
In other news, Director Muneer A. Satter acquired 3,750,000 shares of the firm’s stock in a transaction on Monday, March 27th. The stock was purchased at an average price of $4.00 per share, for a total transaction of $15,000,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Muneer A. Satter acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, June 13th. The stock was purchased at an average price of $3.03 per share, with a total value of $30,300.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 3,845,900 shares of company stock valued at $15,299,428. Company insiders own 29.88% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sei Investments Co. bought a new position in Vital Therapies during the third quarter worth $321,000. State Street Corp increased its position in Vital Therapies by 6.0% in the fourth quarter. State Street Corp now owns 328,091 shares of the company’s stock worth $1,427,000 after buying an additional 18,645 shares in the last quarter. Bank of New York Mellon Corp increased its position in Vital Therapies by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock worth $352,000 after buying an additional 9,120 shares in the last quarter. SG Americas Securities LLC bought a new position in Vital Therapies during the first quarter worth $167,000. Finally, Victory Capital Management Inc. increased its position in Vital Therapies by 9.6% in the first quarter. Victory Capital Management Inc. now owns 2,549,439 shares of the company’s stock worth $10,197,000 after buying an additional 222,824 shares in the last quarter. 26.62% of the stock is owned by hedge funds and other institutional investors.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Vital Therapies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vital Therapies Inc. and related companies.